 Kalie Tommerdahl
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 10 | 2024 | 284 | 3.610 |
Why?
| | Diabetes Mellitus, Type 2 | 12 | 2025 | 2442 | 2.380 |
Why?
| | Diabetes Mellitus, Type 1 | 14 | 2025 | 3628 | 1.570 |
Why?
| | Metformin | 2 | 2023 | 318 | 1.170 |
Why?
| | Insulin Resistance | 5 | 2024 | 1167 | 1.120 |
Why?
| | Albuminuria | 2 | 2024 | 183 | 0.970 |
Why?
| | Prediabetic State | 2 | 2024 | 244 | 0.700 |
Why?
| | Cystic Fibrosis | 2 | 2020 | 1066 | 0.670 |
Why?
| | Kidney | 8 | 2024 | 1386 | 0.670 |
Why?
| | Fructosamine | 1 | 2019 | 15 | 0.650 |
Why?
| | Deoxyglucose | 1 | 2019 | 52 | 0.640 |
Why?
| | Glucose Tolerance Test | 1 | 2020 | 355 | 0.630 |
Why?
| | Serum Albumin | 1 | 2019 | 149 | 0.610 |
Why?
| | Glomerular Filtration Rate | 5 | 2024 | 712 | 0.540 |
Why?
| | Adolescent | 16 | 2025 | 20412 | 0.500 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1001 | 0.380 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 92 | 0.360 |
Why?
| | Hypoglycemic Agents | 4 | 2022 | 1221 | 0.330 |
Why?
| | Humans | 29 | 2025 | 129625 | 0.310 |
Why?
| | Child | 8 | 2025 | 20884 | 0.240 |
Why?
| | Creatinine | 3 | 2022 | 490 | 0.240 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 47 | 0.210 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 122 | 0.210 |
Why?
| | Body Composition | 2 | 2025 | 649 | 0.210 |
Why?
| | Young Adult | 9 | 2025 | 12455 | 0.210 |
Why?
| | Hyperoxia | 1 | 2024 | 90 | 0.210 |
Why?
| | Mitochondria, Muscle | 1 | 2024 | 111 | 0.200 |
Why?
| | Sex Characteristics | 2 | 2025 | 736 | 0.200 |
Why?
| | Receptors, Prolactin | 2 | 2012 | 7 | 0.200 |
Why?
| | Glucosides | 1 | 2022 | 38 | 0.190 |
Why?
| | Glycoproteins | 1 | 2024 | 338 | 0.190 |
Why?
| | Obesity | 3 | 2025 | 2882 | 0.190 |
Why?
| | Benzhydryl Compounds | 1 | 2022 | 66 | 0.190 |
Why?
| | Adiposity | 2 | 2024 | 504 | 0.180 |
Why?
| | Bone Density | 1 | 2025 | 463 | 0.180 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2006 | 0.180 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 114 | 0.180 |
Why?
| | Male | 13 | 2025 | 63670 | 0.170 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 254 | 0.170 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 96 | 0.170 |
Why?
| | Transcriptional Activation | 2 | 2012 | 367 | 0.170 |
Why?
| | Female | 14 | 2025 | 68734 | 0.160 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 248 | 0.160 |
Why?
| | Oxygen | 2 | 2024 | 915 | 0.160 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 197 | 0.160 |
Why?
| | Diabetic Retinopathy | 1 | 2021 | 178 | 0.150 |
Why?
| | Glycation End Products, Advanced | 1 | 2019 | 76 | 0.150 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 581 | 0.150 |
Why?
| | Biomarkers | 3 | 2024 | 3968 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 566 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1005 | 0.140 |
Why?
| | Risk Factors | 2 | 2021 | 9786 | 0.130 |
Why?
| | Cognition | 1 | 2024 | 1129 | 0.130 |
Why?
| | Phenotype | 2 | 2022 | 3075 | 0.120 |
Why?
| | Hemodynamics | 3 | 2024 | 1090 | 0.110 |
Why?
| | Hypoxia | 1 | 2020 | 1084 | 0.100 |
Why?
| | Brain | 1 | 2025 | 2673 | 0.100 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 19 | 0.100 |
Why?
| | HMGN2 Protein | 1 | 2011 | 3 | 0.090 |
Why?
| | Mass Screening | 1 | 2019 | 1190 | 0.090 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 130 | 0.090 |
Why?
| | STAT5 Transcription Factor | 1 | 2011 | 48 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 341 | 0.090 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5075 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 314 | 0.080 |
Why?
| | Cell Nucleus | 1 | 2011 | 584 | 0.070 |
Why?
| | Adult | 6 | 2025 | 35599 | 0.070 |
Why?
| | Insulin | 3 | 2024 | 2326 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2025 | 3378 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1418 | 0.060 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 54 | 0.060 |
Why?
| | Gray Matter | 1 | 2025 | 81 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 248 | 0.060 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 90 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 495 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 109 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 315 | 0.050 |
Why?
| | Threonine | 1 | 2022 | 44 | 0.050 |
Why?
| | Histidine | 1 | 2022 | 60 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 539 | 0.050 |
Why?
| | Prognosis | 2 | 2025 | 3774 | 0.050 |
Why?
| | Lipocalin-2 | 1 | 2022 | 76 | 0.050 |
Why?
| | Lipoproteins | 1 | 2022 | 172 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 117 | 0.050 |
Why?
| | Leucine | 1 | 2022 | 109 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 103 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1028 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 177 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 19 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2022 | 237 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 40 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2133 | 0.040 |
Why?
| | Triglycerides | 1 | 2022 | 528 | 0.040 |
Why?
| | Glucose Clamp Technique | 1 | 2020 | 194 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2012 | 326 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1017 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 1970 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 346 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1592 | 0.040 |
Why?
| | Insulin Infusion Systems | 1 | 2022 | 363 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 487 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2024 | 875 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2020 | 224 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 601 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 387 | 0.030 |
Why?
| | Body Mass Index | 1 | 2025 | 2274 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2012 | 1336 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 588 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 4894 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1613 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3394 | 0.030 |
Why?
| | Genes, Neoplasm | 1 | 2012 | 20 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 55 | 0.030 |
Why?
| | Exercise | 1 | 2024 | 1928 | 0.030 |
Why?
| | Blood Glucose | 1 | 2022 | 2100 | 0.030 |
Why?
| | Prolactin | 1 | 2012 | 97 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 943 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2011 | 317 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 636 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 429 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 840 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 419 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 843 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1713 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2057 | 0.020 |
Why?
| | United States | 1 | 2024 | 13871 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1207 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2835 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1164 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 2124 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2627 | 0.010 |
Why?
| | Models, Biological | 1 | 2011 | 1724 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3186 | 0.010 |
Why?
| | Middle Aged | 1 | 2024 | 31136 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3717 | 0.010 |
Why?
| | Animals | 1 | 2020 | 35391 | 0.010 |
Why?
|
|
Tommerdahl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|